BRAF and melanoma: Here, A375 melanoma cells harboring the BRAF V600E oncogenic mutation, and therefore having constitutively active Ras/RAF signaling, were treated with the highly specific BRAF mutant inhibitor vemurafenib or control vehicle, respectively, and displayed strong negative effects of BRAF inhibitors on EGR1 expression (GEO Profiles: GDS5085/8108370, GSE42872 [40], Figure 5D).